1-5 of 5
Clifton Mo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)

Free
Peter O'Gorman, Jacob Laubach, Ruth Clifford, Clifton Mo, Senthil Kumar, Omar Nadeem, Monique Hartley-Brown, Siobhan Glavey, Shonali Midha, Yuxin Liu, Maja Vase, Keith Pratz, Patrick Hayden, Jessica Liegel, Paul Dowling, Emily Benjamin, Vicky Donachie, Zahra Beers, Olivia McLoughlin, Layla Horwitz, Jacinta Marron, Emma Sueiro, Marc Nolan, David Poretsky, Anna Shevlin, Sarah Beaton, Charlotte Prior, Catherine Piper, Bindu Krishnanivas, Emily Simpson, Elizabeth Karimi, Marissa Davis, Lourdes McAlester, Alanna Allen, Paul Richardson
Journal: Blood
Blood (2025) 146 (Supplement 1): 4030.
https://doi.org/10.1182/blood-2025-4030
Published: 2025
Journal Articles

Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers

Free
Sara Close, Jun Liu, Lara Abousamra, Suhayla Sarhan, Kristine Geary, Sanjana Arji, Claire Shao, Eileen Green, Yuxin Liu, Paul Richardson, John Manis, Corey Cutler, Sarah Nikiforow, Clifton Mo
Journal: Blood
Blood (2025) 146 (Supplement 1): 4185.
https://doi.org/10.1182/blood-2025-4185
Published: 2025
Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Free
Lauren Merz, Rebecca Zon, Susanna Jacobus, Mehmet Samur, Jeffrey Zonder, Abdullah Khan, Hani Hassoun, Larry Anderson, Yvonne Efebera, Tondre Buck, Racquel Innis-Shelton, Monique Hartley-Brown, Sagar Lonial, Erica Campagnaro, Peter Voorhees, Robert Orlowski, Caitlin Costello, Noopur Raje, Eva Medvedova, Philip McCarthy, Carter Milner, Cristina Gasparetto, Mounzer Agha, Krisstina Gowin, Rammurti Kamble, Sundar Jagannath, Nitya Nathwani, Melissa Alsina, Sergio Giralt, Jacob Laubach, Omar Nadeem, Irene Ghobrial, Clifton Mo, Kenneth Anderson, Nikhil Munshi, Paul Richardson
Journal: Blood
Blood (2025) 146 (Supplement 1): 1033.
https://doi.org/10.1182/blood-2025-1033
Published: 2025
Journal Articles

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Free
Zohaib Ahmed, Walid Hamouche, Shonali Midha, Yuxin Liu, Adam Sperling, Clifton Mo, Jacob Laubach, Paul Richardson, Nikhil Munshi, Omar Nadeem
Journal: Blood
Blood (2025) 146 (Supplement 1): 7525.
https://doi.org/10.1182/blood-2025-7525
Published: 2025
Journal Articles

Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results

Free
Clifton Mo, Cristina Gasparetto, Cristiana Costa, Andrew Cowan, Tomer Mark, Yi Chai, Trinayan Kashyap, Jessica Katz, Michael Amatangelo, Paul Richardson
Journal: Blood
Blood (2025) 146 (Supplement 1): 4010.
https://doi.org/10.1182/blood-2025-4010
Published: 2025